

We are co-creators of the Devine, all instrumental in changing and creating  
our world and reality one step, one person, and one  
day at a time.

With this awareness comes responsibility  
and the need to be present and conscious of our actions at every moment.  
Having consciousness means holding this responsibility with absolute respect  
for all life and existence.

We hold the powerful and precious tool for transformation  
in our own hands and hearts,  
one loving thought and action at a time.

Each individual's gift and contribution to the whole will vary,  
but has equal importance.

Martina Hoffman



# Table of Contents

<b>INTRODUCTION</b>	<b>11</b>
<b>FOREWORD</b>	<b>11</b>
<b>INSTRUCTIONS FOR USE</b>	<b>18</b>
<b>THANKSGIVING</b>	<b>20</b>
<b>PART I: KEY PROBLEMS IN LC/PVS</b>	<b>22</b>
<b>INFECTION VS. VACCINATION: IMMUNOLOGICAL EFFECTS</b>	<b>23</b>
THE VACCINATION IS IMMUNOLOGICALLY SIMILAR TO A SERIOUS COURSE	23
VACCINATION AND INFECTION GENERATE DIFFERENT IMMUNITY	25
THE "SPIKE" OF INFECTION AND VACCINATION	30
THE TOXIC EFFECT OF THE SPIKE	33
LONG COVID VS. POST-VACCINE SYNDROME: DIFFERENCES AND SIMILARITIES	34
<b>CLOT FORMATION, MYOCARDITIS AND AMYLOIDS</b>	<b>36</b>
<b>BASICS</b>	<b>36</b>
CLOT FORMATION BY DESTRUCTION OF ENDOTHELIAL CELLS	40
DIRECT ACTIVATION OF THE COAGAGATION SYSTEM BY THE SPIKE	42
SPIKE CAN LEAD TO THE FORMATION OF AMYLOIDS AND PRIONS	46
FIBRIN-AMYLOIDS	47
SPIKE AMYLOIDS	48
AMYLOIDS, BRAIN AND PRIONS	50
<b>SUMMARY OF DIAGNOSTICS &amp; THERAPY</b>	<b>53</b>
<b>MYOCARDITIS</b>	<b>58</b>

**ENDOTHELIITIS & SILENT INFLAMMATION** **62**

---

**ENDOTHELIITIS** **62**

**SILENT INFLAMMATION** **69**

**AUTOIMMUNITY** **76**

---

**THE SPIKE PROTEIN INVITES AUTOREASONS** **77**

**SPECIFIC AUTOANTIBODIES** **82**

**GPCR-AK** **86**

**THERAPY FOR AUTOIMMUNITY** **91**

**PLASMAPHERESIS** **91**

**IMMUNOSUPPRESSION** **94**

**COMBINED THERAPY** **96**

**MITOCHONDROPATHY: THE UNDERTAKEN PROBLEM** **97**

---

**WHAT ARE MITOCHONDRIA?** **99**

**SARS-COV2, THE SPIKE PROTEIN AND MITOCHONDRIA: AN UNFORTUNATELY CLOSE RELATIONSHIP** **105**

**HOW CAN WE MEASURE MITOCHONDRIAL DAMAGE?** **110**

**SEARCH TESTS** **111**

**THE BHI (BIOENERGETIC HEALTH INDEX)** **113**

**THERAPY OF MITOCHONDROPATHY** **116**

**IMPROVEMENT IN MITOCHONDRIAL STRUCTURE** **117**

**IMPROVEMENT IN MITOCHONDRIAL FUNCTION** **118**

**INCREASE IN MITOCHONDRIAL COUNT** **119**

**INCREASE MITOCHONDRIAL OXYGEN SUPPLY** **120**

## **NEUROINFLAMMATION: FIRE IN THE BRAIN**

---

**125**

<b>THE BLOOD-BRAIN BARRIER</b>	<b>131</b>
THE SMELLING RAIL	133
THE INTESTINAL TRACT	134
THE SPIKE AND THE BLOOD-BRAIN BARRIER	136
<b>THE SPIKE IN THE CNS – A DISASTER TAKES ITS RUN</b>	<b>138</b>
<b>ATTACKING BRAIN METABOLISM</b>	<b>140</b>
GENERAL ANTI- INFLAMMATORY	149
<b>THE TREATMENT OF NEUROINFLAMMATION</b>	<b>150</b>
ORAL THERAPY	150
INTRANASAL THERAPY ( IN)	156

## **MASTS CELL ACTIVATION SYNDROME**

---

**161**

<b>WHAT ARE MASTS CELLS?</b>	<b>161</b>
<b>THE MASTS CELL ACTIVATION SYNDROME: MCAS</b>	<b>162</b>
<b>MAS CELLS AND THE SPIKE PROTEIN</b>	<b>165</b>
<b>HISTAMINE RECEPTORS AND HISTAMINE ANTAGONISTS</b>	<b>167</b>
<b>THE MCAS DIAGNOSIS : UNFORTUNATELY NOT SIMPLE</b>	<b>169</b>
<b>THERAPY OF AN MCAS: A BROAD POSITION IS REQUIRED</b>	<b>172</b>
THE DIARY	172
NUTRITION & GUT	173
PEG SENSITIVITY	178
HISTAMINE LIBERATORS AND DAO INHIBITORS	180
MAST CELL STABILIZER	181
ANTI-HISTAMINES	182

---

**VITAMIN D BALANCE** **184**

**BASICS OF VITAMIN D BALANCE** **186**

VITAMIN D SOURCES 186

VITAMIN D VARIANTS: STORED AND ACTIVE FORM 187

THE VITAMIN D RECEPTOR 189

**VDR DEFICIENCY: CAUSES** **192**

VDR DEFICIENCY: CONSEQUENCES **193**

**VITAMIN D AND VDR: MEASUREMENT AND NORMAL VALUES** **197**

**VITAMIN D THERAPY: KNOW HOW** **201**

---

**HORMONAL SYSTEM** **204**

HYPOTHALAMUS AND PHYPHYSIS 206

EPHIPHYSIS 206

THYROID 208

ADRENAL CORTICLE 211

adrenal medulla 214

GONADS 216

PANCREAS 218

---

**PART II: SPECIFIC PROBLEMS IN POST-VACCINE SYNDROME** **221**

---

**THE VACCINES: WHAT ARE WE DEALING WITH?** **222**

**HOW CLASSIC VACCINES WORK** **223**

**GENE-BASED VACCINES** **225**

DNA VACCINES: VECTOR VIRUSES AS CARRIER 227

RNA VACCINES: NANOPARTICLES AS CARRIER 229

**INCORPORATION OF THE SPIKE PROTEIN INTO THE CELL MEMBRANE** **234**

<b>PERSISTENCE: THE VACCINES STAY IN THE BODY LONGER THAN GENERALLY ASSUMED</b>	<b>236</b>
<b>PERSPECTIVE DEAD VACCINES</b>	<b>238</b>
<b><u>V AIDS</u></b>	<b><u>241</u></b>
<b>SYNCYTING: WHY DEATH STARS ARE A REAL PROBLEM</b>	<b>244</b>
<b>INTERFERON DEFICIENCY: EPIGENETIC BLOCKADE</b>	<b>247</b>
<b>NK CELLS: EXHAUSTED KILLERS</b>	<b>250</b>
<b>T-HELPER CELLS: BURN-OUT IN THE GENERAL STAFF</b>	<b>256</b>
<b>TURBO CANCER</b>	<b>261</b>
<b>ADE, T-REG AND INTERFERENCE: INCREASED SUSPENSIBILITY TO CORONA INFECTIONS</b>	<b>265</b>
<b>ADE: INFECTIOUS ANTIBODIES</b>	<b>265</b>
<b>INTERFERENCE: SWAP ONE VIRUS FOR ANOTHER</b>	<b>270</b>
<b>T-REG: "HABITATION" TO SARS-COV2</b>	<b>271</b>
<b>BASICS: VDR, SILENT INFLAMMATION &amp; MITOCHONDRIA</b>	<b>273</b>
<b>IDENTIFY AND TREAT V-AIDS</b>	<b>275</b>
<b>SPECIFIC DIAGNOSTICS AND THERAPY</b>	<b>275</b>
<b>GENERAL WEAK DEFENSE SUPPORT</b>	<b>279</b>
<b>CANCER SCREENING</b>	<b>280</b>
<b><u>PLATE DISORDERS</u></b>	<b><u>284</u></b>
<b><u>PART III: SPECIFIC PROBLEMS IN LONG-COVID</u></b>	<b><u>287</u></b>
<b><u>ORGANIC CHANGES</u></b>	<b><u>288</u></b>

---

**CORONA, MICROBIOME AND CHRONIC INFECTIONS** **292**

**CORONA AND THE MICROBIOME** **292**  
MICROBIOME 294  
INTESTINAL BARRIER DISORDER: LEAKY GUT 296  
VIRUS PERSISTENCE : CHRONIC INFECTIONS **300**

---

**PART IV: IMMEDIATE ACTION, LOGS & APPENDIX** **304**

---

**PROTOCOLS** **305**

**IMMEDIATE ACTION** **305**  
FIRST AID 306  
HOW TO FIND A SUITABLE PRACTICE/ CLINICAL 309  
DIAGNOSTICS: MANDATORY PROGRAM 310  
PREVENTION AND POST-VACCINATION 312  
**THERAPY: CONSIDERATIONS AND TIPS** **314**  
ENDOTHELITIS, MICROCLOTS AND AUTOIMMUNITY 315  
NEUROINFLAMMATION 318  
VITAMIN D BALANCE 319  
MCAS 320  
MITOCHONDRIA 321  
ELIMINATE SPIKE PROTEINS 322  
V-AIDS, TURBO CANCER AND CHRONIC CORONA INFECTION 324  
HORMONAL SYSTEM 325

---

**SHEDDING** **327**

**INITIAL SITUATION AND STATUS OF SCIENCE** **327**  
**SYMPTOMS OF SHEDDING SENSITIVES** **331**

<b>POSSIBLE COUNTERMEASURES</b>	<b>333</b>
<b><u>SYMPTOMS OF LONG-COVID AND POST-VACCINE SYNDROME</u></b>	<b><u>334</u></b>
<b><u>THE REGULATORY STUDIES: HOW TO AVOID SIGNIFICANT STUDIES</u></b>	<b><u>338</u></b>
<b>THE PROBLEM OF TELESCOPING</b>	<b>339</b>
<b>THE PROBLEM OF STUDY SIZE</b>	<b>341</b>
<b>THE PLACEBO PROBLEM</b>	<b>343</b>
<b>THE PROBLEM OF PARTICIPANT SELECTION</b>	<b>344</b>
<b>THE WRONG SURROGATE MARKERS PROBLEM</b>	<b>346</b>
<b>THE MISSING SURROGATE MARKERS PROBLEM</b>	<b>352</b>
<b>THE PROBLEM OF THE CONTROL GROUP</b>	<b>354</b>
<b>RELATIVE AND ABSOLUTE RISK REDUCTION</b>	<b>- 355 -</b>
<b>THE PFIZER CASE : THERE IS NO APPROVAL TRIAL AT ALL</b>	<b>- 358 -</b>
<b>VACCINATION FAILS AT THE POPULATION LEVEL</b>	<b>- 360 -</b>
<b><u>APPENDIX</u></b>	<b><u>- 362 -</u></b>
<b>LIST OF FIGURES</b>	<b>- 362 -</b>
<b>INDEX</b>	<b>- 369 -</b>
<b>IMPORTANT MINUTES AND SUMMARIES</b>	<b>- 376 -</b>
<b>BIBLIOGRAPHY AND REFERENCES</b>	<b>- 380 -</b>